Infliximab has recently been approved for paediatric use, which has been a great improvement for a group of patients lacking therapeutic options.”
“OBJECTIVE: We systematically reviewed the effectiveness of progestogens for prevention of preterm birth among women with prior spontaneous preterm birth, multiple gestations, preterm labor, short cervix, or other indications.
DATA SOURCES: We searched MEDLINE and EMBASE databases for English
language articles published from January 1966 to October 2011.
METHODS OF STUDY SELECTION: We excluded publications that were not randomized controlled trials or had fewer than 20 participants, identifying 34 publications, of which 19 contained data for Bayesian meta-analysis.
TABULATION, INTEGRATION, AND RESULTS: Two reviewers independently extracted data and assigned overall quality ATM/ATR inhibitor clinical trial ratings 3-MA price based on predetermined criteria. Among women with prior preterm birth and a singleton pregnancy (five randomized controlled trials), progestogen
treatment decreased the median risk of preterm birth by 22% (relative risk [RR] 0.78, 95% Bayesian credible interval 0.68-0.88) and neonatal death by 42% (RR 0.58, 95% Bayesian credible interval 0.27-0.98). The evidence suggests progestogen treatment does not prevent prematurity (RR 1.02, 95% Bayesian credible interval 0.87-1.17) or neonatal death (RR 1.44, 95% Bayesian credible interval 0.46-3.18) in multiple gestations. Limited evidence suggests progestogen treatment may prevent prematurity in women with preterm labor MLN4924 mw (RR 0.62, 95% Bayesian credible interval 0.47-0.79) and short cervix (RR 0.52, 95% Bayesian credible
interval 0.36-0.70). Across indications, evidence about maternal, fetal, or neonatal health outcomes, other than reducing preterm birth and neonatal mortality, is inconsistent, insufficient, or absent.
CONCLUSION: Progestogens prevent preterm birth when used in singleton pregnancies for women with a prior preterm birth. In contrast, evidence suggests lack of effectiveness for multiple gestations. Evidence supporting all other uses is insufficient to guide clinical care. Overall, clinicians and patients lack longer-term information to understand whether intervention has the ultimately desired outcome of preventing morbidity and promoting normal childhood development. (Obstet Gynecol 2012; 120:897-907) DOI:http://10.1097/AOG.0b013e3182699a15″
“In this report we describe a case of a 19-year-old woman with a severe to fulminant steroid-resistant ulcerative colitis that was successfully treated with infliximab. Severe to fulminant ulcerative colitis is a potentially life-threatening condition and although the mortality rate has dropped dramatically over the past 40 years, this has not been the case with colectomy which has remained unchanged. Recently, infliximab has been shown to be effective as rescue therapy for steroid-refractory cases.